

Receipt date: 03/14/2006

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
33361US0000
APPLICATION NO.
Not Yet Assigned
APPLICANT
ATADJA ET AL.
FILING DATE
Herewith101057457A7:344
14 MAR 2006

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
AM	2004/052292	6/24/04	WO			<input type="checkbox"/>	<input type="checkbox"/>
AN						<input type="checkbox"/>	<input type="checkbox"/>
AO						<input type="checkbox"/>	<input type="checkbox"/>
AP						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Guo et al., "Co-treatment with histone deacetylase inhibitors suberoylanilide hydroxamic acid (SAHA) enhances Apo-2L/TRAIL-induced death inducing signaling complex and apoptosis of human acute lymphoid leukemia cells," Proceedings of the American Association for Cancer Research Annual Meeting, Vol. 44, p. 154 (2003)
AS	Guo et al., "Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells," Cancer Research, Vol. 64, No. 7, pp. 2580-2589 (2004)
AT	Inoue et al., "Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis," International Journal of Molecular Medicine, Vol. 9, No. 5, pp. 521-525 (2002)

EXAMINER /Nelson Blakely III/ DATE CONSIDERED 09/08/2008

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

See Office Action.

Receipt date: 03/14/2006

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

AT&T DOCUMENT
39365-US
APPLICATION NO.
Not Yet Assigned
APPLICANT
ATADJA ET AL.
FILING DATE
Herewith1010757173614
Sheet 2 of 2
14 MAR 2006
IAP9 REC'D/PC/T/PTO 14 MAR 2006

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA	5,763,223	6/9/98	Goodwin et al.			
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES <input type="checkbox"/> NO <input type="checkbox"/>
	DM	02/22577	3/21/02	WO			<input type="checkbox"/> <input type="checkbox"/>
	BN						<input type="checkbox"/> <input type="checkbox"/>
	BO						<input type="checkbox"/> <input type="checkbox"/>
	BP						<input type="checkbox"/> <input type="checkbox"/>
	BQ						<input type="checkbox"/> <input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

BR	Mitslades et al., "Molecular sequelae of histone deacetylase inhibition in human malignant B cells," Blood, Vol. 101, No. 10, pp. 4055-4062 (2003)
BS	Rosato et al., "Histone deacetylase inhibitors interact in a highly synergistic manner with TRAIL to induce mitochondrial damage and apoptosis in human leukemia cells," Proceedings of the American Association for Cancer Research Annual Meeting, Vol. 43, p. 701 (2002)
BT	

EXAMINER /Nelson Blakely III/ DATE CONSIDERED 09/08/2008

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.B./